High frequency:Low frequency ratios over time.

<p>(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.</p

Serious: Non-serious ratios over time.

<p>(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.</p

The 5 Drugs Studied.

<p>*ADR: adverse drug reaction, EPPV: early post-marketing phase vigilance.</p><p>The 5 Drugs Studied.</p

High prominence:Low prominence ratios over time.

<p>(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.</p

Adverse drug reaction reporting trend for 5 drugs.

<p>Total number of individual case safety reports for (A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.</p